---
reference_id: "PMID:34799033"
title: "Pigmented Lesions in Children: Update on Clinical, Histopathologic and Ancillary Testing."
authors:
- Bartenstein Reusch D
- Hawryluk EB
journal: Dermatol Clin
year: '2022'
doi: 10.1016/j.det.2021.09.003
content_type: abstract_only
---

# Pigmented Lesions in Children: Update on Clinical, Histopathologic and Ancillary Testing.
**Authors:** Bartenstein Reusch D, Hawryluk EB
**Journal:** Dermatol Clin (2022)
**DOI:** [10.1016/j.det.2021.09.003](https://doi.org/10.1016/j.det.2021.09.003)

## Content

1. Dermatol Clin. 2022 Jan;40(1):25-36. doi: 10.1016/j.det.2021.09.003. Epub 2021
 Oct 22.

Pigmented Lesions in Children: Update on Clinical, Histopathologic and Ancillary 
Testing.

Bartenstein Reusch D(1), Hawryluk EB(2).

Author information:
(1)Harvard Combined Dermatology Residency Training Program, 50 Staniford Street, 
Suite 200, Boston, MA 02114, USA.
(2)Department of Dermatology, Massachusetts General Hospital, 50 Staniford 
Street, Suite 200, Boston, MA 02114, USA; Dermatology Section, Boston Children's 
Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: 
ehawryluk@mgh.harvard.edu.

Patients are commonly referred to pediatric dermatology for the evaluation of 
pigmented lesions. For families, pediatricians, and dermatologists alike, 
malignancy is the main fear. In the past few decades, there has been evolving 
literature to inform diagnosis and management. This article provides an update 
on the clinical, histopathologic, and ancillary testing for 3 categories of 
particularly challenging pigmented lesions: congenital melanocytic nevi, 
spitzoid neoplasms, and pediatric melanoma.

Copyright Â© 2021 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.det.2021.09.003
PMID: 34799033 [Indexed for MEDLINE]

Conflict of interest statement: Disclosure D.W. Bartenstein: MRK (stock, self); 
DVA (stock, spouse); ANTM (stock, spouse); PRSC (stock, spouse); AMAG (stock, 
spouse). E.B. Hawryluk: UpToDate, Inc. (royalty, author/reviewer); Purity 
Brands, LLC (consultant); Gritstone Oncology, Inc. (salary, stock spouse); 
PathAI (stock and advisory board, spouse).